Trials / Recruiting
RecruitingNCT06461624
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.
Detailed description
This is a single-arm, dose-escalation, open, exploratory clinical study to evaluate the safety and tolerability, preliminary efficacy and PK/PD characteristics of GPC3 CAR-T cells in the treatment of advanced hepatocellular carcinoma. Primary objectives: To evaluated the safety of GPC3 CAR-T cells in patients with advanced hepatocellular carcinoma. Secondary objectives:To evaluate the preliminary efficacy and PK/PD characteristics of CBG166.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-GPC3 CAR-T | All subjects were intravenous administrated with CBG166. |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2027-07-01
- Completion
- 2027-10-31
- First posted
- 2024-06-17
- Last updated
- 2024-11-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06461624. Inclusion in this directory is not an endorsement.